# Hostile Release Review 2026-08-22

## Scope

Reviewed `origin/main` as Principal Engineer, AppSec, QA lead, and performance reviewer.

This review did not touch production, Supabase state, secrets, deployments, Manus branches, or PR #22 files.

## Collision Result

`TARGET_PATHS=docs/HOSTILE_RELEASE_REVIEW_2026-08-22.md`

`COLLISION=NO`

PR #22 owns the engineering console and control-plane function surface, so console runtime, trace-store, recovery, accessibility, and performance fixes are not written here.

## Verified Checks

- `bash tooling/preflight.sh --all` passed on 116 tracked files.
- Search for secret markers, unsafe shell commands, deploy markers, Supabase mutation markers, unsafe log rendering markers, and hardware claim terms produced no new independently fixable release blocker on `origin/main`.
- Existing documentation correctly states that physical Halo behavior is not measured.

## Findings

| Area | Finding | Action |
|---|---|---|
| Preflight staged blob scanning | `origin/main` still has working-tree-based staged scanning. | Covered by PR #23; no duplicate write here. |
| Preflight path splitting | Line-oriented preflight enumeration can split newline-containing paths. | Covered by Lane 1 stacked branch `codex/preflight-nul-paths`. |
| CI workflow edits | `.github/workflows/verify.yml` is touched by open PRs. | Covered read-only by Lane 8; no workflow write here. |
| Engineering console | Console code exists in PR #22, not `origin/main`. | Read-only for Codex because PR #22 is Manus-owned. |
| Android release TODOs | Flutter template comments remain in Android build files. | Not a release blocker while G8 is blocked and no store release is authorized. |

## Release Gate Status

The repository is not release-ready for public product claims. The current documentation is aligned with that state: G2-G8 remain blocked or unmeasured on `origin/main`.

## No Fix Applied

No additional high-confidence, non-colliding code defect was found in this lane. The durable output is this review artifact so future release work can distinguish already-covered risks from active release blockers.
